Cleveland Biolabs Inc. Nominates Former President of Roswell Park Cancer Institute to Board of Directors

BUFFALO, NY--(Marketwire - May 03, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Board of Directors has decided to nominate David Hohn, MD, former President of Roswell Park Cancer Institute, to its Board of Directors in the upcoming election to be held at the CBLI annual meeting on June 7, 2011.

Dr. Hohn was recruited to Roswell Park Cancer Institute in 1997 to serve as the Institute’s 12th President. Dr. Hohn came to Roswell from the MD Anderson Cancer Center in Houston, Texas, where he served as Vice President for Patient Care from 1993 to 1997. During his 10 years as President and CEO of Roswell Park, Dr. Hohn achieved landmark legislation, creating a new governance model for the Institute, built new research facilities, and recruited a new leadership team in addition to over 160 new clinical and scientific faculty. Under his leadership, Roswell Park’s position as a leader in the national cancer community was reestablished and its operating budget was tripled to $560 million annually. Between 2009 and 2010, the Institute was awarded $104 million to support research grants and contracts, which more than tripled the awards to the Institute when Dr. Hohn was first appointed.

Dr. Hohn was appointed President Emeritus and Executive Director of Health Policy at Roswell Park Cancer Institute upon his retirement in April 2007. He continues his national leadership role in health policy issues, especially as they relate to cancer research and treatment and the training of the next generation of cancer specialists. He served for three years as Chairman of the Board of Directors of the National Comprehensive Cancer Network, an alliance of 21 of the world’s leading cancer centers, and currently serves on that organization’s Executive Committee. In 2007, Dr. Hohn was appointed Vice-Chair of the New York Stem Cell Board, an organization that is promoting and funding stem cell research in New York State. Dr. Hohn has authored numerous peer reviewed publications and pioneered development of new medical and surgical technologies.

Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, commented, “We are thrilled to add Dr. Hohn to our Board of Directors and further strengthen our association. We have worked closely with David since he orchestrated our strategic partnership with Roswell Park during his tenure as President. His 30 years of clinical and administrative experience will be invaluable as we move forward in our development.”

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company’s website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors.

These factors include, among others, the Company’s history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company’s need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company’s R&D grants and contracts; the Company’s failure to successfully and timely develop new products; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company’s inability to obtain regulatory approval in a timely manner or at all; the Company’s collaborative relationships and the financial risks related thereto; the Company’s ability to comply with its obligations under license agreements; the potential for significant product liability claims; and the Company’s ability to comply with various safety, environmental and other governmental regulations. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the “Risk Factors” and “Forward-Looking Statements” described in the Company’s periodic filings with the Securities and Exchange Commission.